Werewolf Therapeutics (HOWL)
(Delayed Data from NSDQ)
$2.19 USD
-0.21 (-8.75%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.19 0.00 (0.00%) 6:38 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Brokerage Reports
Werewolf Therapeutics, Inc. [HOWL]
Reports for Purchase
Showing records 1 - 20 ( 55 total )
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- ESMO 2024 Abstract Titles for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Highlights From the 2024 Wedbush Healthcare Conference
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Postive Ahead of Updates for WTX-124 (2H24) and WTX-330 (4Q24); Reit. Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KOL Feedback on Next Gen IL-2 Landscape Supports WTX-124 as a Best-in-Class Asset
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
WTX-330 First Look: PR in Melanoma, Expansion Underway
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
WTX-124?s Mono/Combo (+PD-1) Profile Remains Encouraging for Solid Tumors
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
May I Have Your Attention Please? Will The Real IL-2 Please Stand Up?
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Werewolf?s WTX-124?s Mono/Combo (+PD-1) Profile Continues to Have Solid Tumors Running Scared
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Listen For the HOWL During ASCO?24, as WTX-124 Takes Another Bite Out of Solid Tumors; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q:24 Financials; WTX-124 and WTX-330 Updates On Track
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY23 Financials; WTX-124 and WTX-330 Updates Planned for Q2
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
WTX-124?s Mono/Combo Data (1H24) Looks to Further Derisk Cytokine Masking Strategy; Reit Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY23 Financials; WTX-124 And WTX-330 Updates Planned for Q2
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
An INDUKINE Tasting Menu-Highlights From Our Werewolf CMO Dinner
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
All Eyes on Addition Interim WTX-124 Data 1H24; Reit. Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A